Visa Inc. – Consensus Indicates Potential 30.2% Upside

DirectorsTalk Interviews

Visa Inc. with ticker code (V) now have 37 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 296 and 220 calculating the average target price we see 261.34. Given that the stocks previous close was at 200.71 this is indicating there is a potential upside of 30.2%. The 50 day moving average now sits at 207.77 and the 200 day moving average is 210.2. The company has a market capitalisation of $422,979m. Find out more information at: https://usa.visa.com

The potential market cap would be $550,751m based on the market concensus.

Visa Inc. operates as a payments technology company worldwide. The company facilitates digital payments among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. In addition, the company offers card products, platforms, and value-added services. It provides its services under the Visa, Visa Electron, Interlink, VPAY, and PLUS brands. Visa Inc. has a strategic agreement with Ooredoo to provide an enhanced payment experience for Visa cardholders and Ooredoo customers in Qatar. Visa Inc. was founded in 1958 and is headquartered in San Francisco, California.

Share on:

Latest Company News

Capture growth investment opportunities in Europe in 2026

Portfolio managers Sam Morse and Marcel Stötzel outline why they continue to see opportunity in Europe in 2026.

Oxford Nanopore Technologies to participate in January investor conferences

Oxford Nanopore Technologies will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the dbAccess UK & Ireland Conference in London during January.

Pantheon International Plc reports solid half-year NAV performance

As at 30 November 2025, Pantheon International Plc’s NAV per share increased to 520.8p, reflecting valuation gains and continued accretive share buybacks.

Great Portland Estates plc completes £51m West End acquisition

Great Portland Estates plc has purchased a long leasehold interest in 10 South Crescent, WC1 for £51 million, adding to its cluster of West End assets near Tottenham Court Road.

GSK’s Shingrix Prefilled Syringe Approved in Europe

GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine.

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements.

    Search

    Search